Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Steg

Showing results (561-570 of 962) with videos related to

Pageof 97
Sort By:
Heart (British Cardiac Society)|January 28, 2021
Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery diseaseMatthias Bossard, Peggy Gao, William Boden, et al.
American Heart Journal|April 24, 2012
Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohortHarvey D White, Harmony R Reynolds, Antonio C Carvalho, et al.
European Heart Journal|November 26, 2008
Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery TrialVenu Menon, Camille A Pearte, Christopher E Buller, et al.
Journal of the American College of Cardiology|November 26, 2013
Procedural volume and outcomes with radial or femoral access for coronary angiography and interventionSanjit S Jolly, John Cairns, Salim Yusuf, et al.
European Heart Journal|May 25, 2026
Interleukin-6 and C-reactive protein prognostic value following acute coronary syndromeJohan Wouter Jukema, Nicolaas J Van Neer, Michael Szarek, et al.
Clinical Cardiology|March 16, 2017
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention TrialDeepak L Bhatt, Ph Gabriel Steg, Eliot A Brinton, et al.
European Heart Journal|September 11, 2019
Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registryEmmanuel Sorbets, Kim M Fox, Yedid Elbez, et al.
American Heart Journal|March 8, 2017
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialB Daan Westenbrink, Marco Alings, Christopher B Granger, et al.
Journal of the American Heart Association|August 23, 2025
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES TrialGregory P Geba, Kusha A Mohammadi, Amy Damask, et al.
European Heart Journal|August 4, 2007
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trialThomas H Wang, Deepak L Bhatt, Keith A A Fox, et al.
Pageof 97

Showing results (561-570 of 962) with videos related to

Sort By:
Pageof 97
Heart (British Cardiac Society)|January 28, 2021
Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery diseaseMatthias Bossard, Peggy Gao, William Boden, et al.
American Heart Journal|April 24, 2012
Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohortHarvey D White, Harmony R Reynolds, Antonio C Carvalho, et al.
European Heart Journal|November 26, 2008
Lack of benefit from percutaneous intervention of persistently occluded infarct arteries after the acute phase of myocardial infarction is time independent: insights from Occluded Artery TrialVenu Menon, Camille A Pearte, Christopher E Buller, et al.
Journal of the American College of Cardiology|November 26, 2013
Procedural volume and outcomes with radial or femoral access for coronary angiography and interventionSanjit S Jolly, John Cairns, Salim Yusuf, et al.
European Heart Journal|May 25, 2026
Interleukin-6 and C-reactive protein prognostic value following acute coronary syndromeJohan Wouter Jukema, Nicolaas J Van Neer, Michael Szarek, et al.
Clinical Cardiology|March 16, 2017
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention TrialDeepak L Bhatt, Ph Gabriel Steg, Eliot A Brinton, et al.
European Heart Journal|September 11, 2019
Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registryEmmanuel Sorbets, Kim M Fox, Yedid Elbez, et al.
American Heart Journal|March 8, 2017
Anemia is associated with bleeding and mortality, but not stroke, in patients with atrial fibrillation: Insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trialB Daan Westenbrink, Marco Alings, Christopher B Granger, et al.
Journal of the American Heart Association|August 23, 2025
Effect of PCSK9 Inhibition With Alirocumab in Patients With Probable Familial Hypercholesterolemia or Type III Hyperlipoproteinemia: Results From the ODYSSEY OUTCOMES TrialGregory P Geba, Kusha A Mohammadi, Amy Damask, et al.
European Heart Journal|August 4, 2007
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trialThomas H Wang, Deepak L Bhatt, Keith A A Fox, et al.
Pageof 97